4//SEC Filing
Azarbarzin Kurt 4
Accession 0001192482-19-000424
CIK 0001561921other
Filed
Nov 12, 7:00 PM ET
Accepted
Nov 13, 8:52 PM ET
Size
30.8 KB
Accession
0001192482-19-000424
Insider Transaction Report
Form 4
TELA Bio, Inc.TELA
Azarbarzin Kurt
Director
Transactions
- Conversion
Common Stock
2019-11-13+19,982→ 280,790 total(indirect: By HighCape Partners QP, L.P.) - Conversion
Series B Preferred Stock
2019-11-13−5,377,928→ 0 total(indirect: By HighCape Partners QP, L.P.)→ Common Stock (217,816 underlying) - Conversion
Warrant (right to buy)
2019-11-13+123,653→ 123,653 total(indirect: By HighCape Partners QP, L.P.)Exercise: $28.65From: 2017-11-13Exp: 2027-01-18→ Common Stock (5,008 underlying) - Conversion
Warrant (right to buy)
2019-11-13+1,665→ 1,665 total(indirect: By HighCape Partners, L.P.)Exercise: $28.65From: 2019-11-13Exp: 2027-01-18→ Common Stock (67 underlying) - Purchase
Common Stock
2019-11-08$13.00/sh+10,220$132,860→ 12,675 total(indirect: By HighCape Partners, L.P.) - Purchase
Common Stock
2019-11-08$13.00/sh+75,901$986,713→ 260,808 total(indirect: By HighCape Partners QP, L.P.) - Conversion
Common Stock
2019-11-13+269→ 12,944 total(indirect: By HighCape Partners, L.P.) - Conversion
Common Stock
2019-11-13+2,931→ 15,875 total(indirect: By HighCape Partners, L.P.) - Conversion
Common Stock
2019-11-13+217,816→ 498,606 total(indirect: By HighCape Partners QP, L.P.) - Conversion
Series A Preferred Stock
2019-11-13−493,357→ 0 total(indirect: By HighCape Partners QP, L.P.)→ Common Stock (19,982 underlying) - Conversion
Series A Preferred Stock
2019-11-13−6,643→ 0 total(indirect: By HighCape Partners, L.P.)→ Common Stock (269 underlying) - Conversion
Series B Preferred Stock
2019-11-13−72,417→ 0 total(indirect: By HighCape Partners, L.P.)→ Common Stock (2,931 underlying) - Conversion
Warrant (right to buy)
2019-11-13−123,653→ 0 total(indirect: By HighCape Partners QP, L.P.)Exercise: $1.16From: 2017-01-18Exp: 2027-01-18→ Series B Preferred Stock (123,653 underlying) - Conversion
Warrant (right to buy)
2019-11-13−1,665→ 0 total(indirect: By HighCape Partners, L.P.)Exercise: $1.16From: 2017-01-18Exp: 2027-01-18→ Series B Preferred Stock (1,665 underlying)
Footnotes (6)
- [F1]Reflects 2,455 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).
- [F2]Reflects 183,907 shares of common stock received by the reporting person as a payment-in-kind dividend on Series A Preferred Stock and Series B Preferred Stock exempt from reporting under Rule 16a-9(a).
- [F3]Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
- [F4]Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.
- [F5]Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.
- [F6]Warrants exercisable for shares of Series B Preferred Stock automatically converted into warrants exercisable for shares of Common Stock upon the closing of the Issuer's initial public offering.
Documents
Issuer
TELA Bio, Inc.
CIK 0001561921
Entity typeother
Related Parties
1- filerCIK 0001792303
Filing Metadata
- Form type
- 4
- Filed
- Nov 12, 7:00 PM ET
- Accepted
- Nov 13, 8:52 PM ET
- Size
- 30.8 KB